Japanese encephalitis future or investigational therapies

Japanese encephalitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Japanese encephalitis from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Japanese encephalitis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Japanese encephalitis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Japanese encephalitis future or investigational therapies
CDC on Japanese encephalitis future or investigational therapies
Japanese encephalitis future or investigational therapies in the news
Blogs on Japanese encephalitis future or investigational therapies
Directions to Hospitals Treating Japanese encephalitis
Risk calculators and risk factors for Japanese encephalitis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Future or Investigational Therapies

There are a number of new vaccines under development. The mouse-brain derived vaccine is likely to be replaced by a cell culture derived vaccine that is both safer and cheaper to produce. China licensed a live attenuated vaccine in 1988 and more than 200 million doses have been given; this vaccine is available in Nepal, Sri Lanka, South Korea and India. There is also a new chimeric vaccine based on the yellow fever 17D vaccine that is currently under development. Initative for Vaccine Research (IVR) monitors and advises on research related to the design of optimal strategies for immunization, including the selection of age groups for catch-up and the definition of at-risk populations, and the impact of vaccination. The duration of protection and booster needs, and well as immunization of special target groups, also require further analysis. Regulatory guidelines for production, quality control and evaluation of novel live, chimeric vaccines are in preparation.